### Edgar Filing: RUBIN PAUL D - Form 4

DUDINIDALIL

| Form 4   | LD                                   |                                   |   |                             |  |  |  |  |  |                     |  |
|--|--------------------------------------|-----------------------------------|---|-----------------------------|--|--|--|--|--|---------------------|--|
| March 22, 20   |                                      |                                   |   |                             |  |  |  |  |  | PPROVAL             |  |
| FORM 4<br>UNITED STATES SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549   |                                      |                                   |   |                             |  |  |  | 3235-0287  |  |                     |  |
| Check this box<br>if no longer<br>subject to<br>Section 16.<br>Form 4 or<br>Form 5<br>obligations<br>may continue.<br>See Instruction<br>See Instruction<br>Section 16.<br>Form 4 or<br>Form 5<br>obligations<br>may continue.<br>See Instruction<br>Section 17(a) of the Public Utility Holding Company Act of 1935 or Section<br>30(h) of the Investment Company Act of 1940 |                                      |                                   |   |                             |  | Expires: January 31,<br>2005<br>Estimated average<br>burden hours per<br>response 0.5<br>n |  |  |  |                     |  |
| 1(b).<br>(Print or Type R  | Responses)                           |                                   |   |                             |  |  |  |  |  |                     |  |
| 1. Name and Address of Reporting Person <u>*</u><br>RUBIN PAUL D   |                                      |                                   | 2. Issuer Name and Ticker or Trading<br>Symbol<br>CRITICAL THERAPEUTICS INC<br>[CRTX] |                             |  |  |  | 5. Relationship of Reporting Person(s) to<br>Issuer<br>(Check all applicable)  |  |                     |  |
| (Last) (First) (Middle)<br>C/O CRITICAL THERAPEUTICS,<br>INC., 60 WESTVIEW STREET  |                                      |                                   | 3. Date of Earliest Transaction<br>(Month/Day/Year)<br>03/22/2006                     |                             |  |  |  | X Director 10% Owner<br>X Officer (give title Other (specify<br>below)<br>President and CEO  |  |                     |  |
|  |                                      |                                   |   | ndment, Da<br>hth/Day/Year) | -                                      |  |  | 6. Individual or Joint/Group Filing(Check<br>Applicable Line)<br>_X_ Form filed by One Reporting Person<br>Form filed by More than One Reporting |  |                     |  |
| (City)   | (State)                              | (Zip)                             | Tabl  | . I. New D                  | ······································ | ••   | 4: <b>.</b>  | Person   | f an Danafiaial                        | ller Oerreed        |  |
| 1.Title of<br>Security<br>(Instr. 3)   | 2. Transaction Da<br>(Month/Day/Year | tte 2A. Dee<br>r) Executio<br>any |   | (A)<br>or                   |  | quired<br>l of (D)   | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4)   | 7. Nature of<br>Indirect<br>Beneficial |                     |  |
| Common<br>Stock  |                                      |                                   |   |                             |  | (2)  |  | 9,866  | Ι                                      | Held by<br>Daughter |  |
| Common<br>Stock  | 03/22/2006                           |                                   |   | М                           | 72,933                                 | D  | \$<br>0.38   | 114,303  | D                                      |                     |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: RUBIN PAUL D - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)           | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactio<br>Code<br>(Instr. 8) | 5. Number of<br>orDerivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                     |
|---|---|---|---|--|--|--|--------------------|---|-------------------------------------|
|   |   |   |   | Code V                                 | (A) (D)  | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |
| Option to<br>Purchase<br>Common<br>Stock<br>(Right to<br>Buy) | \$ 0.38   | 03/22/2006                              |   | М                                      | 72,933   | <u>(2)</u>   | 10/19/2012         | Common<br>Stock   | 72,933                              |

## **Reporting Owners**

| Reporting Owner Name / Address   |          | Re        |                   |            |  |  |  |  |
|--|----------|-----------|-------------------|------------|--|--|--|--|
|  | Director | 10% Owner | Officer           | Other      |  |  |  |  |
| RUBIN PAUL D<br>C/O CRITICAL THERAPEUTICS, INC.<br>60 WESTVIEW STREET<br>LEXINGTON, MA 02421 | Х        |           | President and CEO |            |  |  |  |  |
| Signatures   |          |           |                   |            |  |  |  |  |
| /s/ Scott B. Townsend, Attorney-in-Fact for Paul D. Rubin Pursuant to Power of               |          |           |                   |            |  |  |  |  |
| Attorney   |          |           |                   | 03/22/2006 |  |  |  |  |
| <u>**</u> Signature of F   | Date     |           |                   |            |  |  |  |  |

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents shares held by the daughter of the reporting person. The reporting person disclaims beneficial ownership of these shares(1) except to the extent of his pecuniary interest therein. This report should not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

Of the option to purchase 72,933 shares of Common Stock of Critical Therapeutics, Inc. originally granted on October 9, 2002, one-half(2) of the underlying shares vested in 2003 and the remaining shares vested in 2004, in each case after the completion of a set of goals approved by the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.